Federal Supply Schedule 36F79720D0214
Award Date
9/1/20
Last Date to Order
8/31/25
Federal Agency
Veterans Integrated Service Network 12
Awardee
Chiesi USA Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Fixed Price with Economic Price Adjustment
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
The federal contract IDV is a Blanket Purchase Agreement (BPA) awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Chiesi USA Inc., a specialty pharmaceutical company. The BPA has a ceiling value of $2,250,000 and a period of performance through September 2025. The BPA is issued against Chiesi's Federal Supply Schedule (FSS) 61-IB contract for pharmaceuticals and drugs. Under this vehicle, Chiesi will provide the VA with the iron chelating drug Ferriprox and the...
The U.S. Department of Veterans Affairs (VA) awarded Recordati Rare Diseases Inc., a foreign-owned pharmaceutical manufacturer, a $15.6 million multiple-award Federal Supply Schedule (FSS-61-IB) contract and a $3.1 million single-award Blanket Purchase Agreement to supply specialized orphan drugs and rare disease treatments. The contract vehicles allow the VA to efficiently procure Recordati's portfolio of medications, including Signifor LAR, Carbaglu, Cystadane, Isturisa, and Cystadrops,...
The U.S. Department of Veterans Affairs (VA) has awarded a multiple award Federal Supply Schedule (FSS-61-IB) contract to Sobi, Inc., a foreign-owned, for-profit pharmaceutical company, with a ceiling value of $78 million through July 2025. This contract enables the VA to procure pharmaceuticals and drug products, such as TEGSEDI and ORFADIN, to support healthcare services for veterans. Additionally, the VA National Acquisition Center has awarded a single-award Blanket Purchase Agreement (BPA)...
The Department of Veterans Affairs (VA) awarded a Federal Supply Schedule (FSS) contract, valued at up to $3.5 million, to Calliditas Therapeutics US Inc., a foreign-owned, for-profit pharmaceutical company. The contract, under the Pharmaceuticals and Drugs (FSS-61-IB) schedule, facilitates the procurement of TARPEYO, an innovative treatment for uncontrolled protein in urine due to primary immunoglobulin A nephropathy, a serious renal condition impacting some veterans. In addition to the FSS...
The Department of Veterans Affairs (VA) has awarded a Federal Supply Schedule (FSS) contract, identified as 36F79720D0075, to Vifor (International) AG, a Swiss-based pharmaceutical manufacturer. The contract, under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), enables the VA to efficiently procure critical pharmaceutical products to support healthcare for veterans. Through this contract, Vifor (International) AG has received multiple delivery orders to supply various...
The Department of Veterans Affairs (VA) Veterans Health Administration has awarded a Federal Supply Schedule (FSS) contract (36F79723D0079) to Fennec Pharmaceuticals, Inc., a foreign-owned, for-profit pharmaceutical company. This multiple-award contract has a ceiling value of $1,500,000 and a period of performance through February 29, 2028. It covers the provision of drugs, pharmaceuticals, and hematology-related products under FSS Schedule 65 IB, intended to ensure VA medical centers and...
This federal contract IDV is a multiple-award Federal Supply Schedule (FSS) contract awarded by the Department of Veterans Affairs (VA) to Idorsia Pharmaceuticals US Inc., a foreign-owned, for-profit manufacturer of pharmaceuticals and related products. The $300,000 FSS contract, awarded by the VA's Veterans Integrated Service Network 12, is for the procurement of drugs, pharmaceuticals, and hematology-related products through September 2027. Additionally, Idorsia Pharmaceuticals US Inc. holds a...
The Department of Veterans Affairs (VA) has awarded Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., a $3.1 billion multiple-award Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB). This contract, valid through August 2029, enables the VA and its Veterans Integrated Service Networks (VISNs) to efficiently procure a variety of oncology and specialty medications to support comprehensive healthcare services for veteran patients nationwide. Under...
The Department of Veterans Affairs (VA) has awarded a $19.3 million Federal Supply Schedule (FSS) contract to Servier Pharmaceuticals LLC, a for-profit pharmaceutical company, to provide drugs, pharmaceuticals, and hematology-related products under the FSS-61-IB schedule. This multiple-award contract has a period of performance through September 2025. The VA has placed several firm-fixed price delivery orders against this FSS contract for Servier to supply specialty oncology medications such...
The U.S. Department of Veterans Affairs (VA) has awarded a single-award Blanket Purchase Agreement (BPA) to Ferring Pharmaceuticals Inc., a for-profit manufacturer of pharmaceutical goods, under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The $5.96 million BPA, with a period of performance through March 2026, enables the VA to procure the drug Adstiladrin (nadofaragene firadenovec), a treatment for genitourinary cancers, to support the provision of healthcare services to...